| INTRODUC TI ON
Strategy Goals (GHSS) for Hepatitis. 4 While targeted screening programmes for high-risk populations such as injection drug users are necessary for elimination of Hepatitis C, 5, 6 little has been done to understand what increases in diagnosis and treatment are necessary in the general population of high endemic countries for achieving these goals. Given that the use of DAAs regardless of fibrosis stage is cost-effective, 7 it is crucial that health policies expand treatment access for all HCV-infected individuals. The goal of this study was to use a new modelling approach, grounded in real-life cohort data of diagnosed and treated patients, to compare different linkage to care scenarios to the overall HCV-infected population in Italy. We aimed to evaluate the possible impact of only linked-to-care individuals on overall HCV burden and to identify a possible strategy to achieve the WHO targets by 2030.
| ME THODS

| Study design
Two Markov-disease burden models were developed to assess the current and future HCV disease burden in Italy. The "Italy Polaris" model is grounded in the natural history of HCV progression and forecasts the HCV impact on the general population. A similar HCV disease burden model, grounded in the current distribution of linkedto-care patients of the PITER (Italian Platform for the Study of Viral Hepatitis Therapies) cohort was also developed. 
| PITER cohort
PITER is an ongoing cohort of 9145 (at time of study) consecutively enroled patients from 90 public, general hospitals and university medical centres distributed across Italy. The PITER cohort is considered a representative sample of linked-to-care patients with no treatment access restrictions on the basis of healthcare system reimbursement criteria. 
| AIFA treatment data
Real-life reported treatment data were provided from January 2015 through August 2017 by the Italian Medicines Agency (AIFA).
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AIFA reimbursement criteria included fibrosis stage ≥F3 patients, patients with extrahepatic manifestations in any stage of fibrosis and liver transplant recipients, until the end of 2016. Beginning in 2017, treatment was expanded to all patients independent of fibrosis score. 
| Italy Polaris and PITER adjusted models
For this analysis, two separate models were constructed. First, a
Markov HCV disease progression model (the "Italy Polaris model") was built using previously described methodology 10 to forecast the 
Key Points
• In Italy, the eligible pool of chronic HCV infected patients to treat will run out between 2025-2028, leaving a significant proportion of infected individuals undiagnosed and without access to care.
• Increased case finding in high prevalent birth cohorts of the general population through targeted screening strategies are necessary to achieve the WHO goals for elimination of viral hepatitis.
• treatment age and SVR rate assumptions through 2030. In 2016, 30 400 patients were considered to be newly linked-to-care for treatment annually and 33 700 patients were treated that year.
As no screening strategy is in place in Italy, the number of treated patients was expected to decrease by half by 2020 due to the depleting pool of eligible patients to treat.
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WHO Targets
The WHO Targets scenario identifies the expansion of diagnosis and treatment necessary to achieve the WHO's 2030 targets for incidence, mortality and diagnosis coverage for HCV defined in the GHSS on Viral Hepatitis. 
| Scenarios-PITER adjusted model
Utilizing the PITER cohort data, three scenarios were created representing different assumptions regarding proportions of the prevalent population in 2015 being diagnosed and under care (40%, 60%, and 80% linked to care). The annual number of patients treated, fibrosis restrictions, ages eligible for treatment and SVR were the same between the three scenarios ( Table 2 ). In each PITER scenario, the number of patients to be treated annually following the year 2017 was kept constant. Under the 40% linkage-to-care scenario, it was assumed (given expert feedback), that 40% of the prevalent population (357 000 patients) in Italy in 2015 was diagnosed and under care. 13 Since the exact number of patients linked-to-care remains unknown, the same scenario was then run under the assumption of 60% (510 000 patients) and 80% (680 000 patients) linkage-tocare. The 80% scenario was derived from from a recent study in the Italian general population 13 and the 60% scenario was chosen as the midpoint.
| Sensitivity analysis
To assess the effect of uncertainties in model inputs, we used 
| RE SULTS
| Base 2016 (Italy Polaris Model)
There were an estimated 849 000 (95% UI: 371 000-1 240 000) infected individuals in 2015. The forecasted impact of each scenario on total number of viraemic infections, HCV liver-related morbidity and mortality were compared through 2030 (Figures 1 and 2 
| WHO targets (Italy Polaris Model)
In order to achieve the WHO GHSS targets, treatment was expanded to 38 000 patients annually by 2025; restrictions by fibrosis stage were lifted, and SVR was increased incrementally over the next 10 years to represent the higher efficacy of treatments in coming years (Table 2b) . Total HCV viraemic infections and HCV liver-related morbidity and mortality are expected to decline substantially, by 95%, 90% and 90%, respectively, by 2030 (Figure 2 ). In order to understand the age distribution of the eligible infected individuals for treatment and to suggest strategies to increase case finding for different linkage to care scenarios, the model estimates the age cohorts with the highest prevalence of asymptomatic individuals, as shown in Table 3 
| PITER adjusted model, 40%, 60% and 80% linked-to-care patients
| Sensitivity analysis
The model inputs that had the largest contribution to the uncertainty in the Italy Polaris and PITER adjusted models are shown in more than under the base assumption. The top five factors explained more than 98% of the variability in both models ( Figure 3A,B) .
In addition, we assessed how prevalence may impact the different linkage-to-care scenarios and the related case finding strategies. Given the "low" prevalence rate, the eligible patients to treat would be depleted sooner than under the base case (4). If prevalence was 370 000 infections rather than the 849 000, we would expect the 
| D ISCUSS I ON
Italy has been considered the country with the highest HCV prevalence in Western Europe, with the peak prevalence in older ages (>70 years). [14] [15] [16] However, many studies estimating HCV prevalence in the Italian general population were conducted more than 20 years ago and have shown regional variances. 17 The highest prevalence rates have been reported in Southern Italy, though many of these earlier studies were conducted in smaller, more rural areas. Recent studies have also reported decreasing rates of HCV prevalence in the country. 11, 18, 19 The limitation of HCV therapy is no longer treatment efficacy or adherence, but the identification of available patients to treat. 
21-23
Linkage to care is limited in that no enhanced HCV screening and diagnosis is implemented in the country. The number of prescribers is restricted only to gastrointestinal and infectious disease specialists whom are limited per region. It was recently estimated that there are 1500 residents per general practitioner in Italy, often curbing the availability of referral and linkage to care to a specialist. 13 In addition, no specific strategies for marginalized patients and at-risk groups are implemented at the national level. To assess how the uncertainty in the prevalence estimate impacts the estimated number of eligible patients to treat, the linkage to care scenarios were run on the range of prevalence values (low: 371 000, base: 849 000, high: 1 240 000) to assess when the treated patients may exceed eligible patients ("be depleted"). -Signifies that given the "high" prevalence estimate, the treated patients will not exceed eligible patients and treatment levels can be maintained through 2030.
reported between 20% and 80% of HCV+ individuals are aware of their status. 11, 23 This uncertainty has clear implications for treatment, as the population first needs to be identified in order to be placed in care. While the real number of linked-to-care patients in
Italy remains unknown, the PITER cohort is considered a representative sample of linked-to-care patients in Italy. The PITER adjusted model refers to a population with a mean age of 59 years, which in part reflects that of populations in other parts of the world that have similar epidemiological characteristics (ie individuals infected previously through blood transfusion or nosocomial transmission with historical trends of high incidence of infection).
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As seen in this modelling study, the rate of treatment uptake will decline unless screening and linking diagnosed patients to care is improved. In the country of Georgia, one of the nine countries on track to achieve the WHO Targets by 2030, the number of newly diagnosed patients entering the national treatment programme has fallen in the past year, suggesting that identification and linkage-tocare of HCV-infected patients in the country might be slowing. 26, 27 The potential targeted screening strategies that were produced in this analysis are useful tools that can be used in countries with comparable HCV epidemiology. A similar approach can also be used for countries with different HCV epidemiology, in that it addresses the improvement of diagnosis and the linkage to care-key factors for achieving the elimination goals. 28, 29 Several and 2028, leaving a significant proportion of infected individuals undiagnosed and without access to care. Increased case finding through potential targeted screening strategies are necessary to achieve the WHO goals. This modelling analysis is a useful tool that can be used by different countries to develop screening strategies for HCV elimination.
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